C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.950
+0.105 (2.73%)
At close: Dec 20, 2024, 4:00 PM
3.970
+0.020 (0.51%)
After-hours: Dec 20, 2024, 7:31 PM EST
C4 Therapeutics Employees
C4 Therapeutics had 145 employees as of December 31, 2023. The number of employees decreased by 1 or -0.68% compared to the previous year.
Employees
145
Change (1Y)
-1
Growth (1Y)
-0.68%
Revenue / Employee
$232,193
Profits / Employee
-$727,566
Market Cap
278.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | 99 | 11 | 12.50% |
| Dec 31, 2019 | 88 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Accolade | 2,400 |
| Zynex | 1,100 |
| Amylyx Pharmaceuticals | 384 |
| Vanda Pharmaceuticals | 203 |
| COMPASS Pathways | 186 |
| Foghorn Therapeutics | 116 |
| Sanara MedTech | 108 |
| Sera Prognostics | 57 |
CCCC News
- 13 days ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - GlobeNewsWire
- 3 months ago - C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 3 months ago - C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 3 months ago - C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors - GlobeNewsWire